Petros Pharmaceuticals, Inc. (PTPI)
NASDAQ: PTPI · IEX Real-Time Price · USD
0.713
+0.033 (4.91%)
At close: May 3, 2024, 4:00 PM
0.700
-0.013 (-1.86%)
After-hours: May 3, 2024, 7:56 PM EDT
Petros Pharmaceuticals Revenue
In the year 2023, Petros Pharmaceuticals had annual revenue of $5.82M, a decrease of -2.83%. Revenue in the quarter ending December 31, 2023 was $-364.25K, a -145.64% decrease year-over-year.
Revenue (ttm)
$5.82M
Revenue Growth
-2.83%
P/S Ratio
0.84
Revenue / Employee
$277,257
Employees
21
Market Cap
4.90M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 5.82M | -169.67K | -2.83% |
| Dec 31, 2022 | 5.99M | -1.82M | -23.29% |
| Dec 31, 2021 | 7.81M | -1.75M | -18.29% |
| Dec 31, 2020 | 9.56M | -6.02M | -38.63% |
| Dec 31, 2019 | 15.58M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Exicure | 23.79M |
| Acutus Medical | 7.16M |
| Aditxt | 645.18K |
| Lipella Pharmaceuticals | 449.62K |
| Assure Holdings | 255.00K |
| Oragenics | 37.65K |
PTPI News
- 10 days ago - Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health - Accesswire
- 17 days ago - Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil) - Accesswire
- 4 weeks ago - Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status - Accesswire
- 4 weeks ago - NextTrip Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program - Accesswire
- 6 weeks ago - Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider - Accesswire
- 2 months ago - Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider - Accesswire
- 3 months ago - Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch - Accesswire
- 3 months ago - Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch - Accesswire